Therapeutic Options in the Treatment of Clozapine-Induced Adverse Effects

Journal of Pharmacy Technology

Volumn 20, Issue 3, 2004, Pages 155-164

  Iqbal, Mohammad Masud ^a   Aneja, Alka ^a   Rahman, Atiq ^b   Megna, James L ^c   Yasmin, Laila ^d   Schwartz, Thomas L ^a   Osmany, Saabry ^e   Alam, Mohammed Adnan ^f  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b University of Alabama at Birmingham   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d Elmhurst Hospital   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Alabama Psychiatric Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMITRIPTYLINE; ANTIBIOTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CAPTOPRIL; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; DROPERIDOL; GRANULOCYTE COLONY STIMULATING FACTOR; LITHIUM; LORAZEPAM; MESORIDAZINE; OLANZAPINE; PIRENZEPINE; PROPYLTHIOURACIL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; SULFONAMIDE; TETRAHYDROLIPSTATIN; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE;

ACUTE LEUKEMIA; AGRANULOCYTOSIS; BIPOLAR DISORDER; BLOOD DYSCRASIA; CARDIOMYOPATHY; CATAPLEXY; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DELIRIUM; DEPRESSION; DIABETES MELLITUS; DROWSINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; ECG ABNORMALITY; ENURESIS; EOSINOPHILIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSALIVATION; HYPOTHERMIA; LIVER TOXICITY; MOOD DISORDER; MYOCARDITIS; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NOSE CONGESTION; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANCREATITIS; PERIODIC PARALYSIS; PROLACTIN RELEASE; QT PROLONGATION; REVIEW; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SUICIDAL BEHAVIOR; SWEATING; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; TARDIVE DYSKINESIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREMOR; URINE INCONTINENCE; WEIGHT GAIN; XEROSTOMIA;

EID: 2342594024     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512250402000303     Document Type: Review

References (133)

1. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63:420-4.
2. Feltus MS, Gardner DM. Second generation antipsychotics for schizophrenia. Can J Clin Pharmacol 1999;6:187-95.
3. Hummel B, Dittmann S, Forsthoff A, Matzner N, Amann B, Grunze H. Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders. A case series. Neuropsychobiology 2002;45:37-42.
4. Hammock R, Levine WR, Schroeder SR. Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation. J Autism Dev Disord 2001;31:109-13.
5. Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 2001;932:44-60.
6. Buckley P, Bartell J, Donenwirth K, Lee S, Torigoe F, Schulz SC. Violence and schizophrenia: clozapine as a specific antiaggressive agent. Bull Am Acad Psychiatry Law 1995;23:607-11.
7. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999;60:22-3.
8. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
9. Peruskens J, ed. Prolactin in schizophrenia. London: Franklin Scientific Projects Ltd., 1997:1-44.
10. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360-9.
11. Seeman P. Dopamine receptors and dopamine hypothesis of schizophrenia. Synapse 1987;1:133-52.
12. Richelson E. Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. J Clin Psychiatry 1984;49:331-6.
13. 4. Neuropsychopharmacology 1992;7:261-4.
14. Kraus T, Haack M, Schuld A, Hinze-Selch DH, Kuhn M, Uhr M, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999;156:312-4.
15. Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998;24:381-90.
16. Marinkovic D, Timtijevic I, Babinski T, Totic S. The side effects of clozapine: a four year follow-up study. Progress Neuropsychopharmacol 1994;18:537-44.
17. Brown CS, Markowitz JS, Moore TR, Parker NG. Atypical antipsychotics: part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999;33:210-7. DOI 10.1345/aph.17216
18. Data on file. Broomfield, CO: Sandoz Pharmaceuticals, 1996.
19. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994;55(suppl B):139-42.
20. Alvir JM, Lieberman JA. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994;55:137-8.
21. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine induced agranulocytosis-incidence and risk factors in the United States. N Engl J Med 1993;329:162-7.
22. Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989;50:329-38.
23. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatry Q 1992;63:51-70.
24. Devinsky O, Pacia SV. Seizures during clozapine therapy. J Clin Psychiatry 1994;55:153-6.
25. Toth P, Frankenburg FR. Clozapine and seizures: a review. Can J Psychiatry 1994;39:236-8.
26. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1992;41:369-71.
27. Haller E, Binder RL. Clozapine and seizures. Am J Psychiatry 1990;147:1069-71.
28. Karper LP, Salloway SP, Seibyl JP, Krystal JH. Prolonged postictal encephalopathy in two patients with clozapine-induced seizures. J Neuropsychiatry Clin Neurosci 1992;4:454-7.
29. Hill D. The relationship between schizophrenia and epilepsy. Folia Psychiatr Neurol Neurochir 1948;51:95-111.
30. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
31. Dalkilic A, Grosch WN. Neuroleptic malignant syndrome following initiation of clozapine therapy (letter). Am J Psychiatry 1997;154:81-2.
32. Tsai G, Cristomo G, Rosenblatt ML, Stern TA. Neuroleptic malignant syndrome associated with clozapine treatment. Ann Clin Psychiatry 1995;7:91-5.
33. Karagianis JL, Phillips LC, Hogan KP, LeDrew KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother 1999;33:623-30. DOI 10.1345/aph.18286
34. Campellone JV, McCluskey LF, Greenspan D. Fatal outcome from neuroleptic malignant syndrome associated with clozapine. Neuropsychiatry Neuropsychol Behav Neurol 1995;8:70-3.
35. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-6.
36. Sachdev P, Kruk J, Kneebone M, Kissane D. Clozapine-induced neuroleptic malignant syndrome: review and report of new cases. J Clin Psychopharmacol 1995;15:365-71.
37. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989;146:717-25.
38. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185-202.
39. Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann 2000;30:325-31.
40. Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998;44:378-81.
41. Caroff SN, Mann SC, Keck PE Jr, Francis A. Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000;20:257-9.
42. Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother 2000;34:662-5. DOI 10.1345/aph.19259
43. Robinson D, Fenn H, Yesavage J. Possible association of parotitis with clozapine. Am J Psychiatry 1995;152:297-8.
44. Brodkin ES, Pelton GH, Price LH. Treatment of clozapine-induced parotid gland swelling (letter). Am J Psychiatry 1996;153:445.
45. Hinkes R, Quesada TV, Currier MB, Gonzalez-Blanco M. Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea (letter). J Clin Psychopharmacol 1996;16:462-3.
46. 4 receptor agonist. Eur J Pharmacol 1994;269:R1-2.
47. Szabadi E. Clozapine-induced hypersalivation (letter). Br J Psychiatry 1997;171:89.
48. Berlan M, Montastruc J-M, Lafontan M. Pharmacological prospects for alpha 2-adrenoceptor antagonist therapy. Trends Pharmacol Sci 1992;13:227-82.
49. Pearlmen C. Clozapine, nocturnal sialorrhea, and choking (letter). J Clin Psychopharmacol 1992;12:69-70.
50. Bourgeois JA, Drexler KG, Hall MJ. Hypersalivation and clozapine (letter). Hosp Commun Psychiatry 1991;42:1174.
51. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine-induced sialorrhea (letter). Br J Psychiatry 1991;159:166.
52. Rogers DP, Shramko JK. Therapeutic options in the treatment of clozapine-induced sialorrhea. Pharmacotherapy 2000;20:1092-5.
53. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
54. Bustillo JR, Buchanan RW, Irish D, Breir A. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry 1996;153:817-9.
55. Leadbetter R, Shutty M, Pavalonis D, Vieeg V, Higgins P, Downs M. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992;149:68-72.
56. Hummer M, Kemmler G, Kurz M, Kurzthaler I, Oberhauer H, Fleischhacker WW. Weight gain induced by clozapine. Eur Neuropsychopharmacol 1995;5:437-40.
57. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroeptics? J Clin Psychopharmacol 1999;19:316-21.
58. George TP, Sernyak MJ, Ziedonis DM, Woods SW. Efects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995;56:344-6.
59. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986;143:993-7.
60. Wetterling PJ. Ziprasidone: a new atypical antipsychotic. J Clin Psychiatry 1996;57:40-5.
61. Goodall E, Oxtoby C, Richards R, Watkinson G, Brown D, Silverstone T. Clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br J Psychiatry 1988;153:208-13.
62. Package insert. Xenical (orlistat). Nutley, NJ: Roche Pharmaceuticals.
63. Schwartz TL, Jindal S, Siminescu M, Nihalani N, Azhar N, Tirmazi S, et al. Effectiveness of orlistat versus diet and exercise for weight gain associated with antidepressant use. Psychopharmacol Bull 2002 (In Press).
64. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment (case report). Eur Neuropsychopharmacol 2001;11:181-2.
65. Baruch R, Poulin M, Thakur A, Karagianis J, Raskin J. Amantadine induces weight loss in patients treated with olanzapine. Schizophr Res 2002;53:159.
66. Stoa-Birketvedt G. Effect of cimetidine suspension on appetite and weight in overweight subjects. BMJ 1993;30:1091-3.
67. Stoa-Birketvedt G, Paus PN, Ganss R, Ingebretsen OC, Florholmen J. Cimetidine reduced weight and improves metabolic control in overweight patients with type 2 diabetes. Int J Obes Relat Metab Disord 1998;22:1041-5.
68. 2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000;48:167-8.
69. Morrison J, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159:655-7.
70. Gordon A, Price LH. Mood stabilization and weight loss with topiramate. Am J Psychiatry 1999;156:968-9.
71. Norton J, Potter D, Edwards K. Sustained weight loss associated with topiramate. Epilepsia 1997;38:58.
72. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss (letter). Can J Psychiatry 2000;45:198.
73. Chengappa KN, Levine J, Rathore D, Parapally H, Atzert R. Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case series. Eur Psychiatry 2001;16:186-90.
74. Wu G, Dias P, Chun W, Li G, Kumar S, Singh S. Hyperglycemia, hyperlipemia, and periodic paralysis: a case report of new side effects of clozapine. Prog Neuro Psychopharmacol Biol Psychiatry 2000;24:1395-400.
75. Koponen H, Saari K, Savolainen M, Isohanni M. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review. Eur Arch Psychiatry Clin Neurosci 2002;252:294-8.
76. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.
77. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-65.
78. Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Ir Med J 2002;95:119-20.
79. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry Z001;62:35-41.
80. Nasrallah HA. Pharmacoeconomic implications of adverse effects during antipsychotic drug therapy. Am J Health Syst Pharm 2002;59(22 suppl 8):S16-21.
81. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002;35:205-9.
82. Wirshing DA, Pierre JM, Erhart SM, Boyd JA. Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatr Clin North Am 2003;26:165-90.
83. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
84. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7:377-84.
85. Safferman AZ, Lieberman JA, Kane JM, Syzmanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-61.
86. Cleophas TJM, Kauw FHW. Pressor responses from noncardioselective beta-blockers. Angiology 1988;39:587-96.
87. Testani M. Clozapine-induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994;55:497-8.
88. Patterson TS. In: Yesavage J, ed. Clozapine: a compendium of selected readings. Stanford, CA: Sandoz Pharmaceuticals, 1992:136-8.
89. Chatterton R. Eosinophilia after commencement of clozapine treatment. Aust N Z J Psychiatry 1997;31:874-6.
90. Friedberg JW, Frankenburg FR, Burk J, Johnson W. Clozapine-caused eosinophilic colitis. Ann Clin Psychiatry 1995;7:97-8.
91. Banov MD, Tohen M, Friedberg J. High risk of eosinophilia in women treated with clozapine. J Clin Psychiatry 1993;54:466-9.
92. Barbui C, Campomori A, Bonati M. Clozapine and blood dyscrasias different from agranulocytosis (letter). Can J Psychiatry 1997;42:981-2.
93. Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology 1989;99(suppl):S97-100.
94. Szymanski S, Jody D, Leipsig R, Masiar S, Lieberman N. Anti-cholinergic delirium caused by retreatment with clozapine (letter). Am J Psychiatry 1992;148:1752.
95. Stanilla JK, Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997;58:252-5.
96. Simpson GM, Varga E. Clozapine-a new antipsychotic agent. Curr Ther Res 1974;16:679-86.
97. Baker RW, Chengappa KN, Baird JW, Steingard MD, Christ MA, Schooler NR. Emergence of obsessive-compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-42.
98. Patil VJ. Development of transient obsessive-compulsive symptoms during treatment with clozapine (letter). Am J Psychiatry 1992;149:272.
99. Ghaemi SN, Zarate CA, Popli AP, Pillay SS, Cole JO. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review. Compr Psychiatry 1995;36:267-70.
100. Levkovitch Y, Kronnenberg Y, Gaoni B. Can clozapine trigger OCD? (letter). J Am Acad Child Adolesc Psychiatry 1995;34:263.
101. Cassidy SL, Thaker GK. Addition of fluoxetine to clozapine. Am J Psychiatry 1993;149:1900-1.
102. Warner B, Alphs L, Schaedelin J, Koestler T. Clozapine and sudden death (letter). Lancet 2000;355:842.
103. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
104. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-7.
105. Coulter DM, Bate A, Meyboom RHB, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001;322:1207-9.
106. Wynne J, Braunwald E. The cardiomyopathies and myocarditides. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001:1359-65.
107. Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000;355:1155-6.
108. Wolstein J, Grohmann R, Ruther E, Hippius H. Antipsychotic drugs and venous thromboembolism (letter). Lancet 2000;356:252.
109. Knudson JF, Kortepeter C, Debitsky GM, Ahmad SR, Chen M. Antipsychotic drugs and venous thromboembolism (letter). Lancet 2000;356:252-3.
110. Rechlin T, Claus D, Weis M. Heart rate variability in schizophrenic patients and changes of autonomic heart rate parameters during treatment with clozapine. Biol Psychiatry 1994;35:888-92.
111. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharmacol 1989;8:691-9.
112. Casey D. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57:40-5.
113. Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
114. Griffiths J, Springuel P. Atypical antipsychotics: impaired glucose metabolism. CMAJ 2001;165:943-4.
115. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin, and glucagons in the rat. Neuroendocrinology 1996;63:269-74.
116. Wozniak KM, Linnoila M. Hyperglycemic properties of serotonin receptor antagonists. Life Sci 1991;49:101-9.
117. Lennard-Jones JE. Clinical management of constipation. Pharmacology 1993;47(suppl 1):216-23.
118. Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacodynamics and pharmacokinetics of clozapine. Clin Pharmacokinet 1993;24:161-6.
119. Hummer M, Kurz M, Kurzthaler I, Oberbauer H, Miller C, Fleischhacker WW. Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997;17:314-7.
120. Gaertner HJ, Fischer E, Hoss J. Side effects of clozapine. Psychopharmacology 1989;99:97-100.
121. Lieberman JA. Maximizing clozapine therapy: managing side effects. J Clin Psychiatry 1998;59:38-43.
122. Kellner M, Wiedermann K, Krieg JC, Berg PA. Toxic hepatitis by clozapine treatment (letter). Am J Psychiatry 1993;150:985-6.
123. Larsen JT, Clemensen SV, Klitgaard NA, Nielsen B, Brosen K. [Clozapine-induced toxic hepatitis] Danish. Ugeskrift for Laeger 2001;163:2013-4.
124. Thompson J, Chengappa KN, Good CB, Baker RW, Kiewe RP, Bezner J, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998;13:95-8.
125. Sepulveda VAC, Lopez AE, Yanez LP, Ramirez CR, Escobar PB, Madrazo DGA. [Sodium diphenylhydantoin as a probable cause of pancreatitis] Spanish. Rev Gastroenterol Mex 1999;64:186-9.
126. Bergemann N, Ehrig C, Diebold K, Mundt C, von Einsiedel R. Asymptomatic pancreatitis associated with clozapine. Pharmacopsychiatry 1999;32:78-80.
127. Jubert P. Clozapine-related pancreatitis (letter). Ann Intern Med 1994;121:722-3.
128. Martin A. Acute pancreatitis associated with clozapine use (letter). Am J Psychiatry 1992;149:714.
129. Aronowitz JS, Safferman AZ, Lieberman JA. Management of clozapine induced enuresis (letter). Am J Psychiatry 1995;152:472.
130. Fuller MA, Borovicka MC, Jaskiw GE, Simon MR, Kwon K, Konicki PE. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996;57:514-8.
131. Steingard S. Use of desmopressin to treat clozapine-induced enuresis (letter). J Clin Psychiatry 1994;55:325-6.
132. Richardson DW, Robinson AG. Desmopressin. Ann Intern Med 1985;103:228-9.
133. Frankenburg FR, Kando JC, Centorrino F, Gilbert JM. Bladder dysfunction associated with clozapine therapy. J Clin Psychiatry 1996;57:39-40.